Hyphens Pharma (SGX:1J5) completed the proposed acquisition of tranche 2 sale shares of Ardence Pharma for a total consideration of 10.9 million ringgit, according to a filing with the Singapore Exchange on Friday.
Following the completion of the tranche 2, the company now has an 82% stake in Ardence, a Malaysia-based boutique pharmaceutical company specializing in aesthetic medicine.
In an earlier filing, the company, through its unit Hyphens Pharma, agreed to acquire the remaining 58% stake in Ardence Pharma in three tranches.
Under first tranche, the pharmaceutical company acquired 23% of Ardence Pharma for 6.4 million Malaysian ringgit.
In the second and third tranches, Hyphens Pharma will acquire 17% and 18% of Ardence Pharma, respectively, at an amount mutually agreed between the parties involved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.